2006—2008年我院口服降糖药应用分析

Analysis of Oral Hypoglycemic Drugs Used in Our Hospital from 2006 to 2008

关键词:  口服降糖药  用药频度  药物应用分析

Key words:  oral hypoglycemic drugs  DDDs  analysis of drug use

摘要:

目的 评估我院口服降糖药的应用状况，为临床合理用药提供参考。方法 采用药物限定日剂量(DDD值)分析方法，统计我院2006—2008年口服降糖药的用药频度(DDDs)、销售金额、每日药费(DDC)等数据。结果 二甲双胍、瑞格列奈、阿卡波糖、格列美脲、格列奇特缓释片、罗格列酮钠片的DDDs逐年增长，销售金额亦呈增长趋势，DDDs排名前3位的是二甲双胍、瑞格列奈、阿卡波糖；销售金额排名前3位的是瑞格列奈、二甲双胍、阿卡波糖。销售金额序号与DDDs序号比值在0.5~2.2之间。结论 二甲双胍、瑞格列奈、阿卡波糖在我院口服降糖药使用中占主导地位，尤其新品种在我院得到了广泛的应用。我院口服降糖药的使用基本合理。

Abstract:

OBJECTIVE To evaluate the use of oral hypoglycemic drugs in our hospital in order to provide an reference for rational use of drugs in clinic. METHODS DDDs, sales volume, and daily expenses of drugs in our hospital from 2006 to 2008 were analyzed with the method of DDD analysis. RESULTS DDDs of oral hypoglycemic drugs (Metformin, Repaglinide, Acarbose, Glimepiride, Gliclazide Modified Release, Rosiglitazone Sodium) increased year by year, sales volumes increased slightly. The top 3 oral hypoglycemic drugs in respect of DDDs were Metformin, Repaglinide, Acarbose; The top 3 oral hypoglycemic drugs in respect of sales volume were Repaglinide, Metformin, Acarbose. The ratio of sales volume sequencing to that of DDDs was between 0.5-2.2. CONCLUSION Metformin, Repaglinide, Acarbose were most used in our hospital, especially the new hypoglycemic drugs were widely used. The use of oral hypoglycemic drugs in our hospital is rational in the main.